• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Day 3 Recap: 2024 Society for Pediatric Dermatology Annual Meeting

Catch up on coverage from the third and final day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

SPD Day 3 conference recap

To stay informed with the latest conference insights, subscribe to receive our E-newsletters.

Lisa Swanson, MD, FAAD: The Current Topical Landscape for Pediatric Patients

Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.

Optimizing Pediatric Acne Care with Hormonal Therapy

Andrea Zaenglein, MD, discussed the role of patient counseling and addressing "hormone phobia" in young patients treated with hormonal therapies for acne in her SPD 2024 session.

Reviewing the Latest Developments in Pediatric Non-Steroidal Topicals

Nnena Agim, MD, presented a comprehensive update on non-steroidal topical therapies, highlighting off-label uses and recent FDA approvals in a session at the SPD's annual meeting.

John Browning, MD: Medical Errors, Confirmation Bias, and Emerging Therapies in Pediatric Dermatology

Browning discusses his participation in an SPD 2024 panel discussion, the future of pediatric dermatology, and more.

PODCAST: Food Fight - Drs Treat and Oza Debate Eczema Triggers

In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?

Topical Isotretinoin Shows Promise in Phase 3 ASCEND Trial for Congenital Ichthyosis

TMB-001 0.05% demonstrates promising efficacy and safety in treating moderate to severe congenital ichthyosis, according to a poster presented at the SPD's annual meeting.

Tapinarof Cream 1% Demonstrates Efficacy in Treating Atopic Dermatitis in Young Patients with Skin of Color

Tapinarof cream 1% has proven to be an effective and safe treatment for atopic dermatitis in diverse populations, according to a poster presented at the SPD's annual meeting.

To view all conference coverage from SPD, click here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.